Evidence map›Paper›PMID 29982100›Full record

ArticleTranslational oncology2018

Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients.

Ke Zheng, Jin-Xiang Tan, Fan Li, Hong-Yuan Li, Xiao-Hua Zeng, Bin-Lin Ma, Jiang-Hua Ou, Hui Li, Sui-Sheng Yang, Ai-Mei Jiang and 14 more

Abstract read
In one paragraph

Article in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Overexpression and mutation ofTranslational cancer research · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ke ZhengDepartment of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jin-Xiang TanDepartment of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Fan LiDepartment of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hong-Yuan LiDepartment of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiao-Hua ZengDepartment of Breast Surgery, Chongqing Cancer Institute, Chongqing, China.
Bin-Lin MaDepartment of Breast and Neck Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Province, China.
Jiang-Hua OuDepartment of Breast Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Province, China.
Hui LiDepartment of Breast Surgery, Sichuan Cancer Hospital & Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Sichuan Province, China.
Sui-Sheng YangDepartment of Breast Surgery, Gan Su Province Tumor Hospital, Gansu Province, China.
Ai-Mei JiangDepartment of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Yunnan Province, China.
Qing NiDepartment of Breast Surgery, Guizhou People's Hospital, Guizhou Province, China.
Jian-Lun LiuDepartment of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Guangxi Province, China.
Jin-Ping LiuDepartment of Breast Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Sichuan Province, China.
Hong ZhengDepartment of Breast Surgery, West China Hospital of Sichuan University, Sichuan Province, China.
Yue-YangBreast Surgery, The First Hospital of Kunming, Yunnan Province, China.
Rui LingDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fouth Military Medical University, Xi'an, Shaanxi Province, China.
Jian-Jun HeDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Province, China.
Zhi-Gang LiDepartment of General Surgery, The First Affiliated Hospital of The Medical College, Shihezi University, Xinjiang Province, China.
Jian ZengDepartment of Gastrointestinal/Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Guangxi Province, China.
Tian-Ning ZouBreast Surgery, Yunnan Cancer Hospital & Third Affiliated Hospital of Kunming Medical University, Yunnan Province, China.
Jun JiangBreast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Zhang-Jun SongMammary Department, The Third People's Hospital of Shaanxi Province, China. Electronic address: 723253884@qq.com.
Qi-Lun LiuSurgical Oncology, General Hospital of Ningxia Medical University, Ningxia Province, China. Electronic address: Liuql6311@hotmail.com.
Guo-Sheng RenDepartment of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: rengs726@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeBreast cancer is now recognized as a clinically heterogeneous disease with a wide spectrum of epidemiological and clinicopathologic features. We aimed to evaluate whether epidemiological and clinicopathologic features are associated with the histological tumor grade of breast carcinomas in Western China.

methodsWe retrospectively collected data from the Western China Clinical Cooperation Group and assessed associations between clinicopathologic factors and histological tumor grade in 8619 female breast cancer patients. Patients were divided into two groups: Group I (tumor grade I/II) and Group II (tumor grade III). Univariable analysis and multivariable logistic regression models were used to analyze the relationships between clinicopathologic factors and tumor grade.

resultsPatients presenting with positive axillary lymph nodes, large tumor size (>2 cm), lymphovascular invasion, hormone receptor negativity, human epidermal growth factor receptor 2 (HER-2) positivity, and triple negativity tended to have an increased risk of a high tumor grade. However, the number of pregnancies or births was inversely correlated with the risk of a high tumor grade. In addition, patients presenting with grade III tumors were more likely to receive aggressive treatment, such as adjuvant chemotherapy, anti-HER-2 therapy, and level III axillary lymph node dissection.

conclusionsOur results suggested that several clinicopathologic factors were associated with high tumor grade of breast cancer patients in Western China.

Identifiers

PMID29982100
PMCPMC6051940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.